We compared the risk of death to first ever acute coronary syndrome in women with (n = 625) or without (n = 6633) postmenopausal hormone therapy use.

Of women with ever use of hormone therapy, 42% died within one year as compared with 52% of non-users (OR 0.62, p < 0.001).

Postmenopausal HT use is accompanied with reduced mortality risk after primary acute coronary syndrome.